ImmunityBio Begins Final Analysis of ANKTIVA-BCG Bladder Cancer Trial

• ImmunityBio completed database lock for its 366-patient QUILT-2.005 trial comparing ANKTIVA with BCG against BCG alone in BCG-naïve non-muscle-invasive bladder cancer.
• Previously reported interim results showed longer-lasting complete responses with the combination than with BCG alone.
• Final efficacy analysis is underway, with topline results expected in November 2026.
• A supplemental FDA application remains on track for the fourth quarter of 2026, seeking expansion into BCG-naïve disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610210730BIZWIRE_USPR_____20261021_BW438627) on October 21, 2026, and is solely responsible for the information contained therein.